- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-9966
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
MZ1 co-operates with trastuzumab in HER2 positive breast cancer ; volume:40 ; number:1 ; day:19 ; month:3 ; year:2021 ; pages:1-12 ; date:12.2021
Journal of experimental & clinical cancer research ; 40, Heft 1 (19.3.2021), 1-12, 12.2021
- Creator
-
Noblejas-López, María del Mar
Nieto-Jiménez, Cristina
Galán-Moya, Eva M.
Tebar-García, David
Montero, Juan Carlos
Pandiella, Atanasio
Burgos, Miguel
Ocaña, Alberto
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13046-021-01907-9
- URN
-
urn:nbn:de:101:1-2021050521215560886091
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Noblejas-López, María del Mar
- Nieto-Jiménez, Cristina
- Galán-Moya, Eva M.
- Tebar-García, David
- Montero, Juan Carlos
- Pandiella, Atanasio
- Burgos, Miguel
- Ocaña, Alberto
- SpringerLink (Online service)
Other Objects (12)
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer
Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer
Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer
Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018